169 completed, 50 terminated, 40 recruiting, 40 unknown. 354 Phase 2, 87 Phase 1, 14 Phase 3.
Follow Adenoma: new trials by email Literature Review of Adenoma trials Research Report on Adenoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas Biospecimen Collection, Computed Tomography, Incomplete Freund''s Adjuvant - Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm | Phase 2 | Not yet recruiting | Roswell Park Cancer Institute | 60 | 2026-12-15 | 2026-10-20 |
| Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma Ivonescimab Combined With Chemotherapy - Malignant Pleural Mesothelioma, Advanced | Phase 1 / Phase 2 | Recruiting | Ruijin Hospital | 78 | 2026-11-01 | 2026-10-26 |
| Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis Rapamycin - Familial Adenomatous Polyposis | Phase 2 | Not yet recruiting | University Hospital, Toulouse | 25 | 2026-09-01 | 2026-05-08 |
| FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N) | Phase 1 / Phase 2 | Not yet recruiting | Martin Huellner | 770 | 2026-08-01 | 2026-07-15 |
| SELECTmeso A Trial for Patients With Relapsed Malignant Mesothelioma SELECTmeso1 A Trial of BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma BMS-986504 - Mesothelioma | Phase 2 | Not yet recruiting | University of Southampton | 30 | 2026-05-11 | 2026-05-22 |
| Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma Cemiplimab, Fianlimab, Pemetrexed (Alimta) - Pleural Mesotheliomas | Phase 2 | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 126 | 2026-04-02 | 2026-08-11 |
| Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma Iparomlimab and Tuvoraleimab injection+Bevacizumab+Pemetrexed+Cisplatin - Mesothelioma | Phase 2 | Not yet recruiting | Fudan University | 37 | 2026-04-01 | 2026-04-07 |
| An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis Biopsy Procedure, Biospecimen Collection, EP2/EP4 Antagonist TPST-1495 - Colorectal Carcinoma, Familial Adenomatous Polyposis | Phase 2 | Recruiting | National Cancer Institute (NCI) | 38 | 2026-03-31 | 2026-09-14 |
| A 2-part Phase 1/2 Open-label Trial on ODM-212 ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel - Mesothelioma, Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | Orion Corporation, Orion Pharma | 229 | 2026-03-27 | 2026-10-22 |
| Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma alrizomadlin - Mesothelioma, Malignant Mesothelioma (MM) | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2026-03-16 | 2026-03-17 | |
| Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma EB-MF-CAR-NK-01, Fludarabine, Cyclophosphamide - Malignant Pleural Mesotheliomas | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-04-06 |
| Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma Tegavivint - Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Recruiting | HonorHealth Research Institute | 126 | 2026-02-17 | 2026-03-11 |
| Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors TYK-01054 - Solid Tumor Malignancies, Malignant Mesothelioma (MM) | Phase 1 / Phase 2 | Not yet recruiting | TYK Medicines, Inc | 219 | 2026-01-01 | 2025-12-22 |
| Patients With High-grade Pancreatic Neuroendocrine Tumors Lurbinectedin 4 MG Injection [Zepzelca] - Neuroendocrine Tumor of Pancreas, Pancreatic Neuroendocrine Tumors | Phase 2 | Enrolling by invitation | National Cancer Center, Korea | 46 | 2025-09-23 | 2025-10-01 |
| 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection [18F]FAPI-74, [18F]FDG - Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC) | Phase 2 | Recruiting | National Cancer Institute (NCI) | 320 | 2025-09-09 | 2026-10-29 |
| Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma iparomlimab and tuvonralimab (Dual PD-1/CTLA-4 blockade) + chemotherapy - Malignant Mesothelioma, Mesothelioma | Phase 1 / Phase 2 | Not yet recruiting | National Cancer Center, China | 55 | 2025-09-01 | 2025-08-20 |
| NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study Neoadjuvant chemo-immunotherapy, Extended pleurectomy/decortication in case of reaching operability - Pleural Epithelioid Mesothelioma, Mesothelioma; Pleura | Phase 1 / Phase 2 | Recruiting | University Hospital, Antwerp | 37 | 2025-07-22 | 2025-08-13 |
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors Zanzalintinib, Everolimus - Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET) | Phase 2 / Phase 3 | Recruiting | Exelixis | 440 | 2025-07-21 | 2026-10-30 |
| Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy Ivonescimab - Pleural Mesotheliomas | Phase 2 | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 38 | 2025-06-30 | 2026-08-10 |
| OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition OT-101 - Malignant Pleural Mesothelioma | Phase 2 | Not yet recruiting | Oncotelic Inc. | 63 | 2025-06-01 | 2024-03-15 |
Showing 20 of 354. Sign in to see all of them.
Mesothelioma, Malignant (165) · Mesothelioma (119) · Adenoma, Islet Cell (42) · Carcinoma, Non-Small-Cell Lung (38) · Colorectal Neoplasms (30) · Neoplasms (25) · Insulinoma (24) · Stomach Neoplasms (24) · Lung Neoplasms (23) · Adenomatous Polyposis Coli (22) · Somatostatinoma (22) · Carcinoma, Renal Cell (21) · Esophageal Neoplasms (21) · Neuroendocrine Tumors (21) · Pancreatic Neoplasms (21)
Neoplasms, Glandular and Epithelial (353) · Neoplasms by Histologic Type (352) · Neoplasms (329) · Neoplasms by Site (305) · Neoplasms, Mesothelial (251) · Respiratory Tract Diseases (201) · Lung Diseases (200) · Respiratory Tract Neoplasms (200) · Thoracic Neoplasms (199) · Lung Neoplasms (177) · Pleural Neoplasms (165) · Digestive System Diseases (138) · Digestive System Neoplasms (138) · Mesothelioma (133)
Cisplatin (48) · Pemetrexed (44) · pembrolizumab (24) · Nivolumab (20) · Carboplatin (17) · Gemcitabine (16) · Bevacizumab (12) · Ipilimumab (12) · Cyclophosphamide (11) · Everolimus (9) · Temozolomide (9) · durvalumab (8) · tremelimumab (8) · atezolizumab (7) · Capecitabine (6)
National Cancer Institute (NCI) (42) · Memorial Sloan Kettering Cancer Center (10) · Dana-Farber Cancer Institute (7) · Alliance for Clinical Trials in Oncology (6) · European Organisation for Research and Treatment of Cancer - EORTC (5) · M.D. Anderson Cancer Center (5) · Novartis Pharmaceuticals (5) · Columbia University (4) · Eli Lilly and Company (4) · H. Lee Moffitt Cancer Center and Research Institute (4) · Intergroupe Francophone de Cancerologie Thoracique (4) · Swiss Cancer Institute (4) · The Netherlands Cancer Institute (4) · University Health Network, Toronto (4) · University Hospital, Antwerp (4)
United States (198) · Italy (39) · France (35) · United Kingdom (34) · Canada (25) · Netherlands (24) · Belgium (22) · Spain (22) · China (21) · Australia (19) · Germany (16) · Japan (12) · South Korea (12) · Denmark (10) · Poland (10)
David S Schrump, M.D. (5) · Hedy Kindler (4) · Raffit Hassan, M.D. (4) · Arkadiusz Dudek, MD (3) · Armando Santoro, MD (3) · Dean Fennell (3) · Robert N Taub, MD, PhD (3) · Anne S Tsao (2) · Antonio Lambiase, MD (2) · Arnaud Scherpereel, MD, PhD (2) · Bryan Burt, MD (2) · Charles L. Wiseman, MD, FACP (2)
PMID 31576173, PMID 33358660, PMID 34289971, PMID 37119510, PMID 37279993, PMID 10500494, PMID 11165136, PMID 12565988, PMID 12621133, PMID 14673042, PMID 15084390, PMID 17429100, PMID 17551129, PMID 18006112, PMID 18224661, PMID 18541589, PMID 19258546, PMID 19451433, PMID 19556318, PMID 19652065, PMID 19861511, PMID 19923375, PMID 20056649, PMID 20332274, PMID 20348368, PMID 20406925, PMID 20516268, PMID 20525721, PMID 20530048, PMID 20647340, PMID 21084270, PMID 21684151, PMID 21724580, PMID 21831734, PMID 21899713, PMID 22149065, PMID 22197613, PMID 22353806, PMID 22831987, PMID 22964475, PMID 23170065, PMID 23516312, PMID 23791541, PMID 23860535, PMID 23919274, PMID 24014734, PMID 24035405, PMID 24166893, PMID 24245549, PMID 24445595
U10CA031946 (6), 2015 (5), 2023 (5), U10CA032102 (5), U10CA021115 (4), 2016 (3), P30CA014599 (3), P30CA015083 (3), P30CA016672 (3), 2008 (2), 2014 (2), 2019 (2), N01CM17102 (2), N01CM62205 (2), N01CN35160 (2)